Molbio Diagnostics Limited
ListedMainboardHealthcare · NSE / BSE
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Price Band
₹768 – ₹807
Issue Size
₹1164.62 L Cr
Lot Size
18 shares
GMP
₹116
+14.4%
Est. Listing
₹923
at current GMP
Subscribed
70.26x
overall
Open
10 Aug 2026
Close
12 Aug 2026
Allotment
13 Aug 2026
Refund
14 Aug 2026
Demat Credit
15 Aug 2026
Listing
17 Aug 2026
Last updated about 1 month ago
Live Grey Market Premium
Molbio Diagnostics Limited GMP Today
Last updated: 17 Aug 2026
Current Premium
₹116+14.4%
Issue Price (Upper)
₹807
Band: ₹768 – ₹807
Estimated Listing Price
₹923
Upper price + GMP
Lot Size
18 shares
Min investment ₹14,526
Estimated Profit / Lot
₹2,088
18 × ₹116
Molbio Diagnostics Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹116
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 28 Sep 2026 | +₹116 | 14.4% | ₹923 |
| 26 Sep 2026 | +₹116 | 14.4% | ₹923 |
| 25 Sep 2026 | +₹104 | 12.9% | ₹911 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Molbio Diagnostics Limited Public Issue & Market Profile
Molbio Diagnostics Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,16,46,246 Crores. The shares are offered at a price band of ₹768 to ₹807 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Public Issue & Pricing Context:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Basis of Allotment & Listing Timeline:
Following the close of bidding on 2026-08-12, the basis of allotment is scheduled to be finalized on 2026-08-13. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Kfin Technologies Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Molbio Diagnostics Limited IPO GMP today?
The latest grey market premium for Molbio Diagnostics Limited IPO is ₹116, which indicates an expected listing price of ₹923.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.